SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC

Clinical trial NCT06916546 · COMPLETED

Trial details

NCT number: NCT06916546
Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Status: COMPLETED
Study type: OBSERVATIONAL

Hepatocellular Carcinoma Non-resectable

Start date: 2022-06-01
Primary completion: 2025-01-31
Enrollment: 238

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.